LJI strengthens ties between U.S. and Mexican scientists
“We’re glad to continue our support for this cross-border partnership and expand our work with young scientists and research leaders just across the border.”
Core Service Cryo-EM
Delivering better vaccines
LJI scientists share their visions for more effective, longer-lasting vaccines
Even as SARS-CoV-2 mutates, some human antibodies fight back
A 'cocktail' of human antibodies shows promise in fighting severe SARS-CoV-2 infections
We’ve learned a lot from lymphocytic choriomeningitis virus—now the time has come to fight it
LJI scientists share high-resolution view of the lymphocytic choriomeningitis virus (LCMV) glycoprotein together with a neutralizing antibody
Durable SARS-CoV-2 antibodies bind to two viral targets at once
"Bivalent" antibodies can continue to neutralize Omicron and Omicron lineages
Promising antibody cocktail takes on Ebola virus—and its deadly cousin
LJI team uncovers how one odd antibody does some heavy lifting
From Alpha to Epsilon: Consortium study illuminates surfaces of Spike most resistant to antibody escape
LJI-led Coronavirus Immunotherapeutic Consortium identifies antibody 'communities' with power to stop SARS-CoV-2 variants
A biochemist takes on Lassa virus
Adrian Enriquez, Ph.D., has a different way of looking at viruses
LJI Professor Erica Ollmann Saphire awarded $6.4 million for international efforts to beat COVID-19
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded more than $6.4 million to Dr. Saphire to support research toward COVID-19 antibody therapeutics.
Leading Structural Immunologist Erica Ollmann Saphire will join La Jolla Institute for Immunology
"She is a truly exceptional scientist, who uses molecular insights to bring together scientists and policymakers for scientific advancement and social change"
